SCHEMBL25319481

SCHEMBL25319481

COCC1Cc2c(C(=O)OC)cc(F)c(C#N)c2O1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.35
▸ ALDH1A1 P00352 7/20 0.35
▸ HPGD P15428 7/20 0.35
▸ MAPT P10636 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GAA P10253 4/20 0.33
▸ CHEK1 O14757 1/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ HSD17B10 Q99714 5/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ GRM2 Q14416 2/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ CASP1 P29466 2/20 0.31
▸ CASP7 P55210 2/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPK10 P53779 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29054633 0.85 KDM4E (0.39) KDM4EALDH1A1HPGDKMT2AGAA
SCHEMBL25319598 0.80 BACE1 (0.32) KDM4EALDH1A1HPGDGAA
SCHEMBL25317728 0.80 BACE1 (0.31) KDM4EALDH1A1MAPT
SCHEMBL25045974 0.76 KDM4E (0.38) KDM4EALDH1A1HPGDMAPTRXFP1
SCHEMBL30184728 0.76 KDM4E (0.38) KDM4EALDH1A1HPGDMAPTRXFP1
SCHEMBL30507882 0.76 KDM4E (0.39) KDM4EALDH1A1HPGDMAPTRXFP1
SCHEMBL25045827 0.76 KDM4E (0.39) KDM4EALDH1A1HPGDMAPTRXFP1
SCHEMBL29054679 0.74 ALDH1A1 (0.44) KDM4EALDH1A1HPGDMAPTRXFP1
SCHEMBL25045979 0.74 ALDH1A1 (0.42) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL30184723 0.74 ALDH1A1 (0.42) KDM4EALDH1A1HPGDMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2025-02-20 — — US disclosed
EP-4448109-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS Aurigene Oncology Limited (IN) 2024-10-23 — — EP disclosed
WO-2023114710-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-06-22 — — WO disclosed
WO-2023114710-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KDM4E 506/4885ALDH1A1 1811/4885HPGD 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback